No products in the cart.
MODULE 7: PERIOPERATIVE PHARMACY
Section 2: Post-Op Pain Management & Antiemetics
Once the surgery is complete, the pharmacist’s role shifts to ensuring a smooth, safe, and comfortable recovery. This section is a masterclass in managing the two most common post-operative challenges: pain and nausea. You will learn to apply your deep pharmacological knowledge to technologies and treatment strategies unique to the inpatient setting.
PART 2.1
Patient-Controlled Analgesia (PCA): The Fundamentals
Empowering Patients to Manage Their Own Pain, Safely
What is a PCA? Moving Beyond PRN Injections
In your retail practice, you are accustomed to counseling patients on PRN pain medications, typically oral tablets like oxycodone or hydrocodone. The patient feels pain, takes a tablet, waits 30-60 minutes for relief, and then may have to wait 4-6 hours before they can take another dose. This creates a cycle of peaks and troughs, where the patient may oscillate between being over-sedated and being in significant pain. Patient-Controlled Analgesia (PCA) is a sophisticated method designed to solve this problem for severe, acute post-operative pain. It consists of an infusion pump containing an opioid (most commonly morphine, hydromorphone, or fentanyl) connected directly to the patient’s IV line. The patient is given a button, and when they feel pain, they can press it to self-administer a small, pre-programmed dose of the opioid. This provides immediate relief (within minutes) and allows the patient to titrate their own medication to a level of comfort, keeping the drug concentration within a narrow therapeutic window. This is the ultimate form of personalized medicine, putting the person who feels the pain in control of their own analgesia.
Retail Pharmacist Analogy: The High-Tech Inhaler
Think of how you counsel patients on managing asthma. A PCA combines the concepts of rescue and controller therapy into one sophisticated device.
- The PRN Albuterol Inhaler is the “Demand Dose”: The patient feels shortness of breath (pain), they use their rescue inhaler (press the PCA button), and they get immediate relief. This is a patient-initiated dose for an acute symptom. The “lockout interval” on the PCA is like you telling the patient, “Don’t use your inhaler more than every 4 hours.” It’s a safety feature to prevent overuse.
- The Controller Inhaler (e.g., steroid) is the “Basal Rate”: This is a scheduled, background therapy designed to provide a constant level of control. A patient on a controller inhaler still needs their rescue inhaler for breakthrough symptoms. Similarly, a patient with a PCA basal rate still needs to use the demand button for breakthrough pain. This concept is the key to understanding why combining the two can be so dangerous.
The Core Components of a PCA Order
Every PCA order is a complex prescription with multiple components you must verify. Your meticulous attention to detail is perfectly suited for this high-risk task.
| PCA Component | Definition & Pharmacist’s Insight | Typical Example (Morphine 1 mg/mL) |
|---|---|---|
| Drug & Concentration | The specific opioid and its concentration. Hospitals use standardized concentrations to prevent errors. Your role is to ensure the ordered concentration matches your hospital’s “smart pump” library. | Morphine 1 mg/mL |
| Demand Dose (or “Bolus”) | The amount of drug the patient receives each time they press the button. This is the workhorse of the PCA. | 1 mg |
| Lockout Interval | The minimum time before the patient can receive another demand dose. This is the single most important safety feature, preventing rapid, accidental overdose. | 8 minutes |
| Basal Rate (or “Continuous”) | An optional, continuous infusion of the opioid. This is a high-risk feature, intended only for opioid-tolerant patients or those with severe, unremitting pain (e.g., cancer pain). | 0.5 mg/hour |
| 4-Hour Limit | The maximum total amount of drug (basal + demand doses) a patient can receive in a 4-hour period. This is a “hard stop” safety guardrail. | 30 mg |
PART 2.2
The Pharmacist’s PCA Safety Checklist
Your Role as the Final Guardian Against Catastrophic Errors
PCA errors are consistently identified by the Institute for Safe Medication Practices (ISMP) as a source of catastrophic patient harm, including permanent brain injury and death from respiratory depression. The pharmacist’s verification is the most critical checkpoint in the entire process. Your verification goes beyond the “five rights” and involves a deep clinical and systems-level review.
The Great Debate: The Danger of Basal Rates in Opioid-Naïve Patients
This is the single most important clinical judgment you will make when verifying a PCA order. An opioid-naïve patient is someone who is not chronically taking opioids and therefore has no tolerance. Giving a continuous basal rate infusion to these patients is incredibly dangerous. Why? Because the built-in safety of a PCA is that if the patient gets too sedated from the demand doses, they fall asleep and stop pressing the button. This natural negative feedback loop is protective.
A basal rate eliminates this safety feature. The patient can become sedated, fall asleep, stop pressing the button… but the pump continues to deliver a steady stream of opioid, which can lead to profound respiratory depression and death. The risk is so great that many hospitals have banned the use of basal rates in opioid-naïve post-operative patients altogether.
HIGH-RISK SCENARIO: Basal Rate in an Opioid-Naïve Patient
When you see an order for a PCA with a basal rate, your first question must be: “Is this patient opioid-tolerant?” You must review their home medication list and admission history.
- If the patient is NOT on chronic opioids at home, a basal rate is almost always inappropriate for post-operative pain. It is your absolute duty to contact the prescriber, explain the safety risks of respiratory depression, and recommend removing the basal rate.
- If the patient IS on chronic opioids (e.g., long-acting morphine, fentanyl patch), a basal rate may be appropriate to cover their baseline opioid requirement, but it should be carefully calculated to match their home regimen.
Never assume a prescriber ordered a basal rate for the right reason. Always challenge and verify. This single intervention can save a patient’s life.
PART 2.3
Postoperative Nausea and Vomiting (PONV)
A Multimodal Approach to Ensuring Patient Comfort
PONV is one of the most common and distressing complications after surgery. It’s not just a matter of comfort; severe vomiting can lead to dehydration, electrolyte imbalances, tension on suture lines, and in rare cases, aspiration of gastric contents. Your role is to ensure patients at risk receive appropriate prophylaxis and that breakthrough nausea is treated effectively using a variety of pharmacological mechanisms.
Risk Factor Assessment: The Apfel Score
We can predict a patient’s risk for PONV using a simple, validated tool called the Apfel score. This allows us to tailor the intensity of prophylaxis to the individual patient. It is based on four key risk factors, with one point awarded for each.
| Risk Factor | Points | Associated PONV Risk |
|---|---|---|
| Female Gender | 1 |
|
| History of Motion Sickness or Previous PONV | 1 | |
| Non-smoker | 1 | |
| Use of Postoperative Opioids | 1 |
A high-risk patient (e.g., a female non-smoker with a history of motion sickness who will receive a PCA) should receive prophylaxis with at least two antiemetic agents from different classes.
Multimodal Antiemetic Therapy: Hitting Different Receptors
The key to effective PONV management is using a multimodal approach—attacking the problem from multiple angles by using drugs that act on different neurotransmitter receptors in the brain’s vomiting center. This is far more effective than simply increasing the dose of a single agent.
| Agent | Mechanism | Pharmacist’s “Deep Dive” Insight |
|---|---|---|
| Ondansetron (Zofran®) | Serotonin (5-HT3) Receptor Antagonist | The workhorse for both prophylaxis and treatment. Main side effect is headache. The biggest concern is QTc prolongation, especially with IV administration. You must assess the patient’s baseline QTc and other QTc-prolonging drugs. |
| Dexamethasone | Corticosteroid | Highly effective for prophylaxis when given at the beginning of surgery. Be cautious in diabetic patients as it can cause transient hyperglycemia. A single 4-8 mg dose is standard. |
| Scopolamine Patch | Anticholinergic | Excellent for preventing motion-sickness-related PONV. Must be applied several hours before induction to be effective. Classic anticholinergic side effects. |
| Droperidol | Dopamine (D2) Receptor Antagonist | Extremely effective but fell out of favor due to a black box warning for QTc prolongation. It is making a comeback at very low doses (0.625-1.25 mg IV) where the risk is minimal and the efficacy is high. Requires careful patient selection. |
Clinical Pearl: The Critical Timing of Dexamethasone and Scopolamine
Unlike ondansetron which can be given at any time for treatment, the prophylactic efficacy of dexamethasone and scopolamine is entirely dependent on proper timing.
- Dexamethasone must be given after induction of anesthesia but before surgical incision.
- The Scopolamine patch must be applied several hours before the induction of anesthesia to allow the drug to be absorbed and reach therapeutic levels.
As a pharmacist, when you see these on a patient’s profile, part of your verification is confirming they were ordered and administered according to these critical time windows.
